Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Prospective Therapeutic Applications of Platelet Extracellular Vesicles.

Author information

Affiliations

  • 1. Exopharm Ltd, Level 17, 31 Queen Street, Melbourne, VIC 3000, Australia; Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia.
      Authors
    • Johnson J 1
    • Lichtfuss G 1
    (2 authors)
  • 2. Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
      Authors
    • Wu YW 2
    (1 author)
  • 3. Exopharm Ltd, Level 17, 31 Queen Street, Melbourne, VIC 3000, Australia.
      Authors
    • Blyth C 3
    (1 author)
  • 4. Saskatoon Cancer Centre and College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
      Authors
    • Goubran H 4
    (1 author)
  • 5. Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan; International PhD Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
      Authors
    • Burnouf T 5
    (1 author)

ORCIDs linked to this article

Trends in Biotechnology, 04 Nov 2020, 39(6):598-612
https://doi.org/10.1016/j.tibtech.2020.10.004 PMID: 33160678 

Review

Abstract 

There is much interest in the use of extracellular vesicles (EVs) as a subcellular therapy for regenerative medicine and drug delivery. Blood-borne platelets represent a source of therapeutic EVs that is so far largely unexplored. Advantages of platelets as a cellular source of EVs include their established clinical value, regulated collection procedures, availability in a concentrated form, propensity to generate EVs, and unique composition and tissue-targeting capacity. This review analyzes the unique potential of platelet-derived (p-) EVs as therapeutic modalities and presents their inherent translational advantages for hemostasis, for regenerative medicine, and as drug-delivery vehicles.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.tibtech.2020.10.004

Citations & impact 

Impact metrics

59
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/93761488
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/93761488

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.tibtech.2020.10.004

Supporting
Mentioning
Contrasting
1
136
0

Article citations

Go to all (59) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

Ministry of Science and Technology, Taiwan